William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

William Blair has named Brent Gledhill as CEO. He will be succeeding John Ettelson, who has been appointed William Blair’s chairman. Gledhill joined William Blair as an investment banker in ...

WVMIX - William Blair Mid Cap Value I - Review the WVMIX stock price, growth, performance, sustainability and more to help you make the best investments.

William Blair has named Bryan P. Finkel and Eric G. Roddy as managing directors to its investment banking team. Both will focus on special purpose acquisition company transactions and be based in ...

William Blair and InvestCloud's collaboration wants to solve the 'too much choice, too little time' problem By Justin L. Mack April 12, 2023, 5:35 p.m. EDT 6 Min Read William Blair/InvestCloud ...